Peter J Greasley

11PUBLICATIONS
61CO-AUTHORS
Biologically active moleculesElectrochemical energy storage and conversionFood properties (incl. characteristics and health benefits)Pharmaceutical delivery technologiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 30, 2026
Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system.

|Apr 02, 2026
Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition.

Erik Moedt, Akihiko Koshino, Niels Jongs

|Oct 01, 2024
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.

J David Smeijer, Victor S Wasehuus, Neeraj Dhaun

|Jul 04, 2024
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials.

Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker

|Nov 09, 2023
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.

Subodh Verma, Sunder Mudaliar, Peter J Greasley

|Aug 16, 2022
Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.

Iain B Squire, Anders Gabrielsen, Peter J Greasley

Pageof 2

Frequent Collaborators

3 joint publications

Philip Ambery

3 joint publications

Hiddo J L Heerspink

3 joint publications

Magnus Åstrand

3 joint publications

Anne-Kristina Mercier